



Preparation of Manuscripts/Instruction to Authors

Turkish Respiratory Journal is an official publication of Turkish Thoracic Society in English. The Journal aims to promote scientific eminence in clinical pulmonary medicine and related fields, and provides a forum for distribution of scientific information. The Journal thus publishes original investigations, reviews, case reports, and letters.

The Journal complies with the guidelines issued by the International Committee of Medical Journal Editors (ICMJE), and invites the authors to follow these instructions (Uniform requirements for manuscripts submitted to biomedical journals. JAMA, 1997;277:927-934 or N Engl J Med 1997;336:309-315). The authorship responsibility is also outlined in these guidelines.

Submission by authors of articles and all kinds of correspondence to the Journal is received with the understanding that all or any part of the work has not been and will not be published elsewhere. Previous publication of the related material in an abstract form less than 400 words are acceptable, and should be indicated in the title page. Authors have the responsibility for the language of the articles.

The manuscripts should be submitted to “**Toraks Derneği, Turkish Respiratory Journal Editörlüğü, Ege Üniversitesi Tıp Fakültesi Göğüs Hastalıkları AD 35 100 Bornova, İzmir, Turkey**”. The manuscripts and all types of correspondence should be submitted as one original typescript and four high quality duplicate copies including the text, tables, figures and photographs. A 3.5-inch floppy disk or CD including all parts of the submitted manuscript (except the photographs) is required. The files should have the format of Microsoft Word for Windows. The file name(s) as well as software name/version should be indicated on the label of the floppy disk or CD.

All manuscripts and other correspondence are subject to editorial review. The editor reserves the right to reject or return the submitted material to the corresponding author if the requirements are not uniformly completed. The editorial board reserves the right to ask for and evaluate the data reported in the submitted manuscript. One copy of the manuscript and figures will be returned to the corresponding author if it is not accepted for publication.

TRANSFERS OF AUTHOR COPYRIGHTS

Authors are kindly invited to send a signed copy of the copyright release form to Turkish Thoracic Society along with their manuscripts during submission. This form is printed at the end of this document and may be copied. Each author should sign this copyright release form, and the title of the manuscript as well as the date of signature should be included. Manuscripts without copyright release form will not be considered for publication.

After transfer of the copyright and acceptance of the submitted work for publication, the manuscripts become the permanent property of the Journal. The related work may not be published elsewhere in whole or in part, without the written permission from the Journal.

ETHICS OF INVESTIGATIONS

Turkish Respiratory Journal requires the authors to specify whether ethical standards are met in their research. Manuscripts that do not properly comply with the ethical issues for humans or animals will not be considered for publication. Investigations performed on human subjects should have the prior approval of their institutional committee on human research. The authors of the manuscript should provide a declaration that informed consent was obtained from the subjects.

FINANCIAL DISCLOSURE

Authors must also reveal any financial involvement in any organizations related to the subject reported in the manuscript. This disclosure should be printed on a separate page and signed by the authors.

MANUSCRIPT SECTION

All part of the manuscripts should be double-spaced on white bond paper (ISO A4- 212 x 297 mm) with margins of at least 25 mm. Only one side of the paper should be printed. Pages should be numbered consecutively beginning with the title page.

Manuscripts on observational or experimental studies should include these sections in the order indicated: Title page, Abstract, Key Words, Introduction, Material and Methods, Results, Discussion, Acknowledgements and References. Tables and Figure legends should follow the manuscript text, and will be numbered consecutively. Each section (tables, figure legends, etc) should begin on

a separate page. Case reports should consist of the following sections: Introduction, Case Report, Discussion and Conclusion.

TITLE PAGE

The title page should include the title of the study, the author(s)' names, their academic or professional affiliations, and the name and address for every author. The authors may consult the Medical Subject Headings, published by the National Library of Medicine, available online at <http://www.nlm.nih.gov/mesh/meshhome.html>.

ABSTRACT

A structured abstract for original investigations should be organized to include the following subtitles in the same order: 1) Study objectives; 2) Design; 3) Setting; 4) Patients or Materials; 5) Intervention(s); 6) Measurements and Results; 7) Conclusions. Each subtitle should begin as a separate line. The abstract should not exceed 250 words. Abstracts for case reports and articles that are not investigational should be limited to no more than 100 words and may be in summary form (unstructured). At least three key words should be provided at the end of the abstract.

ABBREVIATIONS

All abbreviations used in the manuscript should be clearly defined on a separate sheet. Each abbreviation should be written in full definition in the manuscript at its first mention, and noted in parenthesis after the full word(s).

REFERENCES

References should be numbered consecutively by Arabic numerals in parentheses in the order they are first cited in the manuscript. The references used only in tables or figure legends should be numbered in accordance with the order the particular table or figure cited in the text. The references should appear in a separate sheet in the same order of numerical citations in the manuscript. All authors will be listed when there are less than or equal to three. If there are more than three authors, the first three authors will be cited followed by "et al". References from non-English journals should be translated into English. The journal titles of references should be abbreviated as

shown in Index Medicus. Examples of references are as follows:

1. Fergusson DM, Crane J, Beasley R, et al. Perinatal factors and atopic disease in childhood. *Clin Exp Allergy* 1997;27:1394-401.
2. Collins J, Dhillon P, Goldstraw P. Practical bronchoscopy. 1st Ed. London: Blackwell Scientific Publications; 1987.
3. Berger AJ. Control of breathing. In: Murray JF, Nadel JA, Eds. *Textbook of Respiratory Medicine*. 2nd Ed. Philadelphia. W.B. Saunders Company; 1994, p. 199-218.

TABLES

Tables should be self-explanatory and as few as possible. They should be numbered consecutively in the manuscript. Each table should be printed double-spaced on a separate page. They should have a short title. There should not be more than ten columns.

ILLUSTRATIONS

All types of illustrations (photographs, radiographs, CT scans, etc.) should be submitted as high quality print photographs. Original material (radiographs, CT scans, etc.) is not accepted. Each illustration should be numbered consecutively according to its mention in the text. The sequence number, name of the manuscript and an arrow indication of the top side should be marked on the back side of the illustration. Each illustration should have a descriptive legend, and all legends should be grouped and printed on a separate page.

COPYRIGHT ASSIGNMENT

"Please find attached our manuscript entitled (.....) which we submit for consideration to be published in Turkish Respiratory Journal. We, as the authors, have read and signed the form covering the authorship criteria and responsibility. We declare that all or any of the work related has not been and will not be published elsewhere except in an abstract form less than 400 words. We agree that all copyright of the related material is transferred to Turkish Respiratory Journal after acceptance of the submitted manuscript for publications."

This statement should be signed by **all authors**.

- A**
- Açıkel Ü. 6(1):53
 Akçoral A. 6(1):50
 Akgün M. 6(2):95
 Akkaya E. 6(1):56
 Akkoçlu A. 6(3):135
 Akman C. 6(1):39
 Alagöz A. 6(1):32
 Alan M.S. 6(2):113
 Alpaydın A.B. 6(1):42
 Alper H. 6(1):50
 Altın S. 6(2):113;
 6(3):131
 Altınöz S. 6(1):50
 Arınç S. 6(3):149
 Arslan Z. 6(2):113
 Aslan Ş. 6(2):95
 Ataran D. 6(1):10
 Atasever A. 6(1):42
 Aydoğan Ö.T. 6(3):161
 Aysan T. 6(1):42
 Azdaki N. 6(1):10
- B**
- Bapat V. 6(3):164
 Baran R. 6(3):149-53
 Baran R. 6(3):172
 Başay N. 6(3):169
 Başoğlu Ö.K. 6(1):22
 Bayındır Ü. 6(2):73
 Bayız H. 6(3):169
 Bayrak N. 6(3):149
 Bayrak Y. 6(3):159
 Baysal B. 6(2):113
 Beder S. 6(1):4
 Berkoğlu M. 6(3):169
 Berktaş B. 6(3):169
 Bıçakçı B. 6(1):28
 Bilgili G. 6(1):50
 Boskabady M.H. 6(1):10
 Bozbaş Ş.S. 6(2):89
 Bölükbaşı Y. 6(1):28
- C**
- Can D. 6(1):46-50
 Ceberut K. 6(2):116
 Ceylan E. 6(1):36
 Chousem E.U. 6(3):149-72
 Coşar D. 6(2):109
- Ç**
- Çalışır H.C. 6(1):32;
 6(2):105
 Çelik P. 6(2):78
 Çelikel S. 6(2):116
 Çetinçelik Ü. 6(3):131
 Çetinkaya E. 6(2):113
 Çımrın A.H. 6(3):135
 Çok G. 6(2):84
- D**
- Danacı A.E. 6(3):145
 Demir A. 6(3):131
 Demir E. 6(1):46
 Demir İ. 6(3):131
 Demir T. 6(1):39
 Demirağ F. 6(3):169
 Demiryontar D. 6(3):149
 Deveci F. 6(3):139
 Dilege S. 6(3):159
 Dilege Ş. 6(2):102
 Dilek İ. 6(3):149
 Dimov R. 6(2):67
 Dinç G. 6(2):78
 Dinçer S.İ. 6(3):131
 Doğan B. 6(2):84
 Durucu M. 6(3):153
 Düzgün S. 6(1):56
- E**
- Elaldı N. 6(3):166
 Erden E.Ş. 6(3):139
 Erekuş S. 6(1):4
 Ermiş H. 6(2):119
- G**
- Gaid M. 6(3):164
 Goran K. 6(1):15
 Gökırmak M. 6(2):119
 Göksel T. 6(2):73
 Görgüner M. 6(2):95
 Gülcü A. 6(3):135
 Gülen F. 6(1):46
 Güneylıoğlu D. 6(1):56
 Güngör G. 6(1):28
- H**
- Havlıcu Y. 6(2):78
- I-İ**
- Irena K. 6(1):15
 Işık B. 6(1):19
 Işık M.R. 6(1):19
 Işık S.R. 6(1):19
 İtil O. 6(3):135
 İkiz A.Ö. 6(3):135
 İlhan N. 6(3):139
- K**
- Kabaroğlu C. 6(2):73
 Kalaycı G. 6(2):102;
 6(3):159
 Kaptanoğlu M. 6(2):109;
 6(3):166
 Karaali Z. 6(2):113
 Karabay Ö. 6(1):36
 Karaca N. 6(3):145
 Karakurt Z. 6(3):153
 Kargı A. 6(1):53
 Karnak D. 6(1):4
 Kayacan O. 6(1):4
 Kaynar H. 6(2):95
 Kendir M. 6(2):113
 Kılınç O. 6(3):135
 Köksal D. 6(1):4
 Köksal V. 6(3):131
 Köseoğlu D. 6(2):116
 Kumral E. 6(3):161
 Küçük Ç.U. 6(3):153;
 6(1):56
 Küçüker F. 6(1):56
- L**
- Lang-Lanzdunski L. 6(3):164
 Lodi G. 6(1):15
- M**
- Maden E. 6(1):28
 Meral M. 6(2):95
 Mirici A. 6(2):95
 Mutaf İ. 6(2):73
 Mutlu L.C. 6(2):119
 Mutluay N. 6(3):169
 Muz M.H. 6(3):139
- N**
- Nadir A. 6(2):109;
 6(3):166
 Nart D. 6(1):42

O

Osma E. 6(1):53
Ozvaran M.K. 6(3):172

Ö

Önen A. 6(1):36-53
Öner F.E. 6(2):89
Özcan C. 6(1):46
Özhan M. 6(2):84;
6(3):161
Özkan B. 6(3):169
Özmen D. 6(2):73
Özmen İ. 6(1):28
Özşahin S. 6(3):166
Özturâ İ. 6(3):135
Özvaran K.M. 6(3):149

P

Pazarlı P. 6(3):153
Polat P. 6(2):95

R

Risto L. 6(1):15

S

Sağlam L. 6(2):95
Sanisoglu B. 6(3):172
Savaş R. 6(1):42-6
Sayiner A. 6(1):22
Sayiner A.A. 6(1):22

Sazak H. 6(1):32;
6(2):105
Sevinç C. 6(3):135
Seyfikli Z. 6(2):116
Silistreli E. 6(1):36
Solak Z.A. 6(2):73
Somay A. 6(3):172
Soydan S. 6(1):46
Soylu N. 6(1):39
Stefanov C. 6(2):67

Ş

Şahbaz S. 6(3):135
Şahin E. 6(2):109
Şakar A. 6(2):78;
6(3):145
Şanlı A. 6(1):36-53
Şavkılıoğlu E. 6(1):32;
6(2):105
Şener G. 6(3):135
Şimşek A. 6(2):89
Şipit T. 6(2):105

T

Tahaoğlu K. 6(1):28
Tanaç R. 6(1):46
Tanju S. 6(2):102;
6(3):159
Toker A. 6(2):102;
6(3):159
Tor M.M. 6(3):149

Törün T. 6(1):28
Trajanka T. 6(1):15
Tunç M. 6(2):105

U

Uchikov A. 6(2):67
Uçan E.S. 6(3):135
Ulubay G. 6(2):89
Ulus F. 6(2):105
Uzman Ö. 6(3):149

Ü

Ünal E.S. 6(2):102

Y

Yarkin T. 6(3):153
Yazıcıoğlu Ö. 6(3):153
Yeğinsu A. 6(2):116
Yenigün A. 6(1):46
Yıldırım Ç.A. 6(3):145
Yılmaz A. 6(1):56
Yolaçan H. 6(1):19
Yorgancıoğlu A. 6(2):78;
6(3):145
Yuceege M.S. 6(3):172
Yüksel H. 6(3):145

Z

Zeytinoğlu A. 6(1):22

A

aberrant right subclavian artery, 6(1):39-41
 acute bacterial exacerbation, 6(1):22-7
 acute respiratory failure, 6(1):32-5
 aneurysm, 6(1):39-41
 antibiotics, 6(1):22-7
 aortic arch anomaly, 6(1):50-2
 ARDS, 6(2):105-8
 asbestos, 6(3):149-52
 asthma, 6(1):10-4
 asthma, 6(2):116-8
 asthma, 6(3):145-8

B

BAL, 6(2):73-7
 blood, 6(2):73-7
 blunt chest trauma, 6(3):164-5
 body mass index, 6(3):139-44
 bronchial asthma, 6(2):119-22
 bronchiectasis, 6(1):46-9
 bronchiectasis, 6(2):84-8
 bronchitis index, 6(1):4-9
 bronchodilatory effect, 6(1):10-4
 bronchoscopy, 6(3):172-4

C

cardiopulmonary by-pass, 6(3):159-60
 Castleman disease, 6(1):46-9
 chemo-radiotherapy, 6(3):169-71
 Chlamydia pneumoniae, 6(1):22-7
 chronic bronchitis, 6(1):4-9
 chronic obstructive pulmonary disease (COPD), 6(1):19-21
 chronic obstructive pulmonary disease, 6(1):22-7
 chronic obstructive pulmonary disease, 6(1):32-5
 chronic obstructive pulmonary disease, 6(3):139-44
 clinical and laboratory findings, 6(2):95-101

complication, 6(1):36-8
 complication, 6(2):109-12
 complications, 6(1):15-8
 computed tomography, 6(1):39-41
 COPD, 6(2):78-83; 6(2):84-88; 6(2):89-94
 CPAP compliance, 6(3):135-38
 CPAP side effects, 6(3):135-38
 cyst, 6(2):109-12

D

decortication surgery, 6(1):36-8
 de-escalation therapy, 6(2):67-72
 demyelination, 6(3):161-3

E

encephalomyelitis, 6(3):161-3
 endobronchial tuberculosis, 6(2):119-22
 environmental exposure, 6(3):149-52
 exercise capacity, 6(2):89-94
 extramedullary hematopoiesis (EMH), 6(1):42-5

F

family, 6(3):145-8
 feeding intolerance, 6(1):50-2
 flexible bronchoscopy, 6(1):28-31

G

genetic polymorphism, 6(3):131-4
 granulomatous inflammation, 6(2):113-5
 GSTM1, 6(3):131-4

H

hemorrhagic pleural effusion, 6(1):42-5

hydatid disease, 6(2):102-4
 hydatid, 6(2):109-12

I

imipenem/cilastatin, 6(2):67-72
 infancy, 6(1):50-2
 infection, 6(2):84-8
 inflammatory endobronchial polyp, 6(2):116-8
 inhalation technique, 6(1):10-4
 inhaled bronchodilators, 6(2):89-94
 inhaled corticosteroids, 6(2):119-22
 intensive care unit, 6(1):32-5
 invasive, noninvasive, 6(3):153-8

L

leiomyoma, 6(3):172-4
 leptin, 6(3):139-44
 lung cancer surgery, 6(3):159-60
 lung cancer, 6(2):73-7
 lung cancer, 6(3):131-4
 lung protective ventilation, 6(2):105-8
 lung, 6(1):53-5
 lymphoepithelioma, 6(3):169-71
 lymphoepithelioma-like carcinoma of the lung, 6(3):169-71
 lymphoproliferative disorders, 6(1):46-9

M

Macklin's effect, 6(3):164-5
 malignant mesothelioma, 6(3):149-52
 malonyldialdehyde (MDA), 6(1):19-21
 mechanical ventilation, 6(3):153-8

mediastinitis, 6(3):166-8
 mediastinum, 6(1):42-5
 midazolam, 6(1):28-31
 mortality, 6(1):32-5
 mortality, 6(3):153-8
 mucosal biopsy, 6(1):4-9
 multi-cavitary lesions, 6(3):172-4
 myasthenia gravis, 6(1):15-8
 Mycoplasma pneumoniae,
 6(1):22-7

N

necrotizing, 6(3):166-8
 noninvasive, 6(3):153-8

O

occupational exposure,
 6(3):149-52

P

paracoccidioidomycosis,
 6(2):113-5
 paraoxonase (PON1), 6(1):19-21
 patient comfort, 6(1):28-31
 PEEP, 6(2):105-8
 plasma cell granuloma, 6(1):53-5

pneumomediastinum, 6(3):164-5
 polyp, 6(2):116-8
 primary lung cancer, 6(1):56-8
 prognostic factors, 6(1):15-8;
 6(1):32-5
 psychosocial assessment,
 6(3):145-8
 pulmonary alveolar microlithiasis,
 6(2):105-8
 pulmonary artery, 6(2):102-4
 pulmonary artery, 6(3):159-60
 pulmonary embolism, 6(2):95-101
 pulmonary function tests,
 6(1):10-4
 pulmonary resection, 6(2):102-4
 pulmonary, 6(2):109-12

Q

quality of life, 6(2):78-83

R

respiratory distress, 6(1):50-2

S

sedation, 6(1):28-31
 smoking, 6(1):19-21

spiral CT angiography,
 6(2):95-101
 spontaneous pneumothorax,
 6(1):56-8
 St. George's Respiratory
 Questionnaire, 6(2):78-83
 status asthmaticus, 6(3):153-8
 sternal closure, 6(3):166-8
 surgery, 6(1):53-5

T

thoracic incisional tuberculosis
 fistula, 6(1):36-8
 thymectomy, 6(1):15-8
 treatment, 6(3):161-3
 tuberculosis pleuritis, 6(1):36-8
 tuberculosis, 6(2):113-5
 tuberculosis, 6(3):161-3
 tumor markers, 6(2):73-77
 tumor necrosis factor- α ,
 6(3):139-44
 tumor, 6(2):116-8

V

vascular invasion, 6(1):53-5
 vascular ring, 6(1):50-2
 ventilator-associated pneumonia,
 6(2):67-72